CoreValve's 18-French Revalving(TM) System Demonstrated 'Live' at TCT 2006.The percutaneous ReValving[TM] procedure was used to non-surgically implant a new aortic aortic pertaining to or emanating from the aorta. See also aortic arch. aortic aneurysm occurs most often in dogs, where it is caused by Spirocerca lupi larvae, turkeys and primates, causing dyspnea, cyanosis and coughing. bioprosthesis over the diseased heart valve of an 88-year-old female patient who was too high-risk to undergo open-heart surgery IRVINE, Calif. -- CoreValve (www.corevalve.com) announced today that its third-generation, proprietary aortic heart valve was implanted successfully Co non-surgically Co in a 'high-risk' patient using CoreValve's percutaneous, 18-French ReValving[TM] System, at the 18th annual 'Transcatheter Cardiovascular Therapeutics' (TCT TCT The Capital Times (Madison, WI newspaper) TCT Transcatheter Cardiovascular Therapeutics TCT The Coroner's Toolkit TCT Trans Canada Trail TCT Tcl Core Team TCT Tsukuba College of Technology (Japan) ) scientific symposium sponsored by the Cardiovascular Research Foundation (CRF CRF abbr. chronic renal failure CRF Chronic renal failure ). TCT is one of the largest interventional vascular medicine meetings in the world. Dr. Eberhard Grube and Dr. Ulrich Gerckens of the HELIOS Heart Center, Siegburg, Germany, performed the ReValving procedure 'live' via satellite television from the "cath lab" of the HELIOS Heart Center for a TCT audience in Washington, D.C. comprised of interventional cardiologists and industry business-development executives. "Today's successful 'live' ReValving procedure is part of the safety and efficacy clinical trials for our smaller 18-French system and, when combined with the excellent results of nearly 100 previous cases, demonstrates that interventional cardiology interventional cardiology Cardiology The subspecialty of cardiology dedicated to the diagnosis, medical and mechanical therapy, pre- and post-procedure management of adult patients with acute and chronic forms of cardiovascular disease amenable to catheter-based treatment of structural heart disease is no longer just a hope for the future, but a reality today," said Jacques SE[umlaut umlaut (  m`lout) [Ger.,=transformed sound], in inflection, variation of vowels of the type of English man to men. ]guin, M.D., Ph.D., Founder, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CoreValve. Of special note: The 'live' ReValving[TM] procedure at TCT used CoreValve's own proprietary porcine porcine /por·cine/ (por´sin) pertaining to swine. porcine pertaining to pig. See also hog (1), swine. porcine circovirus 1 a nonpathogenic virus. pericardium pericardium: see heart. aortic heart valve, delivered via CoreValve's small 18-French-sized catheter, and required less than 15 minutes to be implanted. As a result, this patient was not only able to avoid open-heart surgery to treat her defective aortic heart valve, but also is expected to require minimal rehabilitation before enjoying substantially enhanced quality of life. About CoreValve Founded in 2001, privately held CoreValveCowhich is headquartered in Irvine, CaliforniaCohas developed a proprietary delivery system for percutaneous heart valve replacement Heart Valve Replacement Definition Heart valve replacement is a surgical procedure during which surgeons remove a damaged valve from the heart and substitute a healthy one. , based on a novel catheter-and-self-expanding-frame approach on a beating heart, thus avoiding open-heart surgery. The CoreValve procedureCowith the proprietary CoreValve Percutaneous ReValving[TM] SystemCocan be performed in a cardiac "cath lab" just like angioplasty and stenting, resulting in less trauma to the patient and substantial cost-savings to the healthcare system. For more information about CoreValve, visit the Company's Web site at www.corevalve.com. Forward-Looking Statements This news release contains certain "forward-looking" statements under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These "forward-looking" statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of CoreValve, are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements. Factors that could cause or contribute to such differences may include, but are not limited to, risks relating to the protection of intellectual property, changes to governmental regulation of medical devices, the FDA's approval of new products, the impact of competitive products, changes to the competitive environment, the acceptance of new products in the market, conditions of the interventional cardiology industry and the economy and other factors. (Caution: the CoreValve ReValving[TM] System will not be available in the USA for clinical trials or for commercialization until further notice. Non-USA clinical investigations are in progress. Not available for sale.) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion